NCT02694874View on ClinicalTrials.gov

Rosiglitazone Adjunctive Therapy for Severe Malaria in Children

NACompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

December 31, 2021

Conditions
Malaria
Interventions
DRUG

Rosiglitazone

This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria

DRUG

Placebo

This is the placebo control

Trial Locations (1)

CP1929

Centro de Investigação em Saude da Manhiça, Manhiça

All Listed Sponsors
collaborator

University Health Network, Toronto

OTHER

collaborator

Barcelona Institute for Global Health

OTHER

lead

Centro de Investigacao em Saude de Manhica

OTHER

NCT02694874 - Rosiglitazone Adjunctive Therapy for Severe Malaria in Children | Biotech Hunter | Biotech Hunter